Author Affiliations: Hepato-Pancreato-Biliary Surgical Unit (Drs Frampton, Pai, Jiao, and Spalding) and Division of Oncology (Dr Krell), both in Department of Surgery and Cancer, and Department of Gastroenterology (Dr Vlavianos), Imperial College, Hammersmith Hospital, London, England.
We thank Moriya and Traverso1 for their recent report presenting data from their longitudinal cohort study describing the recurrence of intraductal papillary mucinous neoplastic (IPMN) lesions in the pancreatic remnant after previous partial resection. Some of these data were also discussed in a recent review article.2 The study by Moriya and Traverso1 further reinforces the difficulties that we face when treating IPMN disease and presents some interesting findings, some of which have already been described by others. In our opinion, this cohort study1 has added to our understanding of IPMN recurrence, and we are therefore grateful to Moriya and Traverso1 for their efforts. A few points, however, deserve mention.
Frampton AE, Pai M, Krell J, Vlavianos P, Jiao LR, Spalding DRC. The “Malignant Truth” About the Recurrence of Pancreatic Intraductal Papillary Mucinous Neoplasms. Arch Surg. 2012;147(10):977-980. doi:10.1001/archsurg.2012.2287